The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy

[1]  Maria Chiara Rendace,et al.  Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy , 2022, Journal of clinical medicine.

[2]  M. Mancini,et al.  Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia , 2022, OncoTargets and therapy.

[3]  A. E. Eşkazan,et al.  Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. , 2021, Blood advances.

[4]  M. Bonifacio,et al.  Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy , 2021, PharmacoEconomics - Open.

[5]  H. Negi,et al.  PCN231 Humanistic and Economic Burden in Patients with Chronic Myeloid Leukemia – A Review of the Literature , 2021 .

[6]  Jie Jin,et al.  Global, Regional, and National Burden of Chronic Myeloid Leukemia, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 , 2020, Frontiers in Oncology.

[7]  P. Patwardhan,et al.  Targeted Literature Review of Patient Reported Outcomes (PROs) in Chronic Myeloid Leukemia (CML) Patients Receiving Second and Later Lines of Treatment , 2020 .

[8]  G. Saglio,et al.  Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors , 2020, Leukemia.

[9]  C. Schiffer,et al.  European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia , 2020, Leukemia.

[10]  M. Baccarani,et al.  Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. , 2019, Blood advances.

[11]  L. Akard,et al.  Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. , 2018, Clinical lymphoma, myeloma & leukemia.

[12]  M. Deininger,et al.  Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. , 2017, Hematology/oncology clinics of North America.

[13]  E. Jabbour,et al.  Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase , 2017, Journal of medical economics.

[14]  C. Gambacorti-Passerini,et al.  Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. , 2017, European journal of cancer.

[15]  C. Buske,et al.  Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Paul W Dickman,et al.  Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Malone,et al.  Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia , 2016, Current medical research and opinion.

[18]  M. Konopleva,et al.  Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. , 2015, The Lancet. Haematology.

[19]  C. Lucioni,et al.  Valutazione di costo-efficacia di ponatinib nella terapia della leucemia mieloide cronica in Italia , 2015 .

[20]  J. Griffin,et al.  Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.